New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
10:02 EDTUMPQ, SIG, SGEN, SLB, RDS.A, RTOKY, MATX, KKR, ITW, HFC, GOL, E, DB, CRR, BRCM, AINV, AXP, ACMPOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Access Midstream (ACMP) upgraded to Buy from Neutral at Ladenburg... American Express (AXP) upgraded at Guggenheim... Apollo Investment (AINV) upgraded to Buy from Neutral at SunTrust... Broadcom (BRCM) upgraded to Outperform from Perform at Oppenheimer... CARBO Ceramics (CRR) upgraded to Neutral from Sell at Guggenheim... Deutsche Bank (DB) upgraded to Overweight from Neutral at JPMorgan... Eni SpA (E) upgraded to Buy from Hold at Deutsche Bank... GOL Linhas (GOL) upgraded to Outperform from Market Perform at Raymond James... HollyFrontier (HFC) upgraded to Outperform at Wells Fargo... Illinois Tool Works (ITW) upgraded to Buy from Hold at Argus... KKR (KKR) upgraded to Outperform from Neutral at Credit Suisse... Matson (MATX) upgraded to Buy from Hold at BB&T... Rentokil (RTOKY) upgraded to Outperform from Neutral at Credit Suisse... Royal Dutch Shell (RDS.A) upgraded to Buy from Hold at Deutsche Bank... Schlumberger (SLB) upgraded to Overweight from Neutral at HSBC... Seattle Genetics (SGEN) upgraded to Buy from Neutral at UBS... Signet Jewelers (SIG) resumed with an Overweight from Neutral at JPMorgan... Umpqua Holdings (UMPQ) upgraded to Equal Weight from Underweight at Barclays.
News For A;SLB;SGEN;SIG;UMPQ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
12:32 EDTSGENAnalysts differ on Seattle Genetics outlook after data
Subscribe for More Information
10:02 EDTSGENOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTSGENOn The Fly: Pre-market Movers
Subscribe for More Information
08:18 EDTAAgilent risk/reward favorable into spin-off, says Leerink
Subscribe for More Information
08:18 EDTAAgilent risk/reward favorable into spin-off, says Leerink
Subscribe for More Information
08:18 EDTSGENSeattle Genetics downgraded at BofA/Merrill
As previously reported, BofA/Merrill downgraded Seattle Genetics to Underperform from Neutral. The firm said AETHERA data for interim overall survival advantage was not significant and could reinforce Adcetris' role as a salvage therapy as opposed to a frontline option. Price target lowered to $34 from $40.
07:43 EDTSGENSeattle Genetics outlook still positive, says RBC Capital
Subscribe for More Information
06:16 EDTSGENSeattle Genetics downgraded to Underperform from Neutral at BofA/Merrill
September 29, 2014
16:20 EDTAAgilent says regulatory authorities close past FCPA probe
Agilent disclosed in a filing that on September 6, 2013, Agilent Technologies disclosed in its Form 10-Q that it had initiated an internal investigation relating to certain sales of company products through third party intermediaries in China and compliance by company employees in China with the requirements of the U.S. Foreign Corrupt Practices Act and other applicable laws and regulations. The company further disclosed that it had voluntarily advised the United States Department of Justice and the United States Securities and Exchange Commission of the investigation. On September 15, the company received a letter from the SECís Division of Enforcement stating that its investigation had been completed and that the Division of Enforcement did not intend to recommend any enforcement action against the company by the SEC. On September 24, the company received a letter from DOJ stating that DOJ had closed its inquiry into the matter, citing the companyís voluntary disclosure and thorough investigation.
13:07 EDTSGENSeattle Genetics weakness a buying opportunity, says Credit Suisse
Credit Suisse said Seattle Genetics top-line AETHERA data was significantly positive for the primary endpoint and expects full results in December at ASH to provide a meaningful update. The firm would use weakness as a buying opportunity and reiterates its Outperform rating and $51 price target.
12:59 EDTSGENSeattle Genetics positive data largely as expected, says Piper Jaffray
Piper Jaffray says the Seattle Genetics' positive top-line data from the Phase III ATHERA trial of ADCETRIS for consolidation therapy in high risk Hodgkin's lymphoma patients following stem cell transplant was largely as expected. Piper sees the potential for label expansion, but keeps an Underweight rating on the stock with a $26 price target.
11:02 EDTAAgilent announces collaboration with University of Toronto
Agilent announced a collaboration with scientists at the University of Torontoís Donnelly Centre for Cellular and Biomolecular Research to produce a comprehensive metabolomics multiple-reaction monitoring library and methodology, using Agilentís Infinity 1290 UHPLC and 6460 triple quadrupole mass spectrometry system.
06:49 EDTSGENSeattle Genetics, Takeda announce positive data from Phase 3 trial of Adcetris
Seattle Genetics and Takeda Pharmaceutical announced that patients with Hodgkin lymphoma who received ADCETRIS as consolidation therapy immediately following an autologous stem cell transplantation lived significantly longer without disease progression compared to patients who received placebo. The phase 3 clinical trial, known as AETHERA, compared the use of single agent ADCETRIS to placebo in 329 patients with HL who were at risk of relapse. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL. The AETHERA trial met its primary endpoint with ADCETRIS treatment resulting in a statistically significant improvement in progression-free survival versus placebo as assessed by an independent central review committee, which equates to a 75% improvement in PFS. PFS was assessed after a minimum of two years post initiation of treatment for all study patients. A pre-specified interim analysis of overall survival showed no statistically significant difference between the treatment arms. Patients on both study arms with progression of HL received a variety of subsequent therapies. Notably, most patients on the placebo arm received ADCETRIS after progression. A further analysis of overall survival is planned in 2016.
05:47 EDTSGENSeattle Genetics to host conference call
Subscribe for More Information
September 26, 2014
17:59 EDTSGENSeattle Genetics up nearly 4% after hours after setting date for ADCETRIS data
07:22 EDTAAgilent management to meet with Jefferies
Meeting to be held in the Mid-Atlantic area on October 2 hosted by Jefferies.
September 25, 2014
10:06 EDTSLBOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:06 EDTSLBSchlumberger upgraded to Outperform from Sector Perform at Iberia
Subscribe for More Information
September 24, 2014
09:07 EDTSGENSeattle Genetics reports additional data from Phase 1 trial of ADCETRIS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use